PTM Biosciences
Proteomics-based Products for Personalized Medicine
Company Overview
Snapshot
Founded in November 2012 by Elinor Dahan, PhD and Yifat Merbl, PhD, PTM Biosciences operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on advancing personalized medicine through proteomics-based products.
Business overview
PTM Biosciences is a Health Tech & Life Sciences company specializing in proteomics-based products and tools for personalized medicine. The company develops and commercializes Post Translational Modifications Profiling technology, conceived at Harvard Medical School, to reveal the physiological state of diseases. This technology provides key information for identifying novel drug targets, elucidating drug mechanisms of action, and discovering predictive biomarkers. By measuring PTM activity from clinical samples, PTM Biosciences generates patient-specific, activity-based signatures to facilitate personalized medicine, serving the pharmaceutical and life sciences industries.
Log in to access full profile ›Company Intelligence Q&A
- What is PTM Biosciences' primary focus?
- PTM Biosciences is dedicated to advancing personalized medicine by developing proteomics-based products and tools for disease diagnosis, disease management, and drug development.
- Who are the founders of PTM Biosciences?
- PTM Biosciences was co-founded by Elinor Dahan, PhD and Yifat Merbl, PhD.
- What core technology does PTM Biosciences utilize?
- The company utilizes a proprietary technology called Post Translational Modifications Profiling, which was conceived at Harvard Medical School.
- What are the applications of PTM Biosciences' technology?
- PTM Biosciences' technology uncovers the potential of protein modifications to reveal the actual physiological state of a disease, providing information for identifying novel drug targets, elucidating drug mechanisms, and discovering predictive biomarkers.
- What future developments are in PTM Biosciences' pipeline?
- Future developments include applying its PTM profiling platform for the analysis of liquid biopsies of melanoma and SLE patients to generate diagnostic biomarkers for disease detection, prediction, and monitoring.